SCHEMBL2113588

SCHEMBL2113588

Cc1cc(C(=O)Nc2cnc(OCC(F)(F)F)c(-c3ccc(Cl)cc3)c2)n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.49
KIT P10721 4/20 0.46
ABL1 P00519 1/20 0.45
PTGS2 P35354 3/20 0.43
KCNH2 Q12809 2/20 0.40
BRAF P15056 2/20 0.40
NR1I2 O75469 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CNR2 P34972 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
RAF1 P04049 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAP4K1 Q92918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2113611 0.88 CNR1 (0.48) CNR1PTGS2KCNH2BRAFSCN5A
SCHEMBL2116818 0.85 CNR1 (0.51) CNR1ABL1PTGS2KCNH2BRAF
SCHEMBL2112797 0.84 CNR1 (0.49) CNR1PTGS2SMN1; SMN2
SCHEMBL2115870 0.83 CNR1 (0.56) CNR1PTGS2KCNH2CNR2SCN5A
SCHEMBL2114245 0.83 CNR1 (0.50) CNR1PTGS2KCNH2BRAFCYP3A4
SCHEMBL17866271 0.83 CNR1 (0.45) CNR1PTGS2KCNH2BRAFSCN5A
SCHEMBL2112441 0.82 CNR1 (0.52) CNR1KCNH2SCN5ASCN2ASCN10A
SCHEMBL2113292 0.82 CNR1 (0.52) CNR1KCNH2CYP2C9SCN5ASCN2A
SCHEMBL2117015 0.82 CNR1 (0.52) CNR1PTGS2KCNH2SCN5ASCN2A
SCHEMBL2113414 0.82 CNR1 (0.54) CNR1ABL1PTGS2KCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2627637-B1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2016-06-29 EP disclosed
US-8410107-B2 N-pyridin-3-yl or N-pyrazin-2-yl carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US disclosed
US-8410107-B2 N-pyridin-3-yl or N-pyrazin-2-yl carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US disclosed
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 US disclosed
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES APOB, CETP, NPC1L1 CNR1 68/4885KIT 2512/4885ABL1 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.